Combination of Physicochemical Tropism and Affinity Moiety Targeting of Lipid Nanoparticles Enhances Organ Targeting
Source abstract
Abstract
Two camps have emerged for targeting nanoparticles to specific organs and cell types: affinity moiety targeting and physicochemical tropism. Here we directly compare and combine both using intravenous (IV) lipid nanoparticles (LNPs) designed to target the lungs. We utilized PECAM antibodies as affinity moieties and cationic lipids for physicochemical tropism. These methods yield nearly identical lung uptake, but aPECAM LNPs show higher endothelial specificity. LNPs combining these targeting methods had >2-fold higher lung uptake than either method alone and markedly enhanced epithelial uptake. To determine if lung uptake is because the lungs are the first organ downstream of IV injection, we compared IV vs intra-arterial (IA) injection into the carotid artery, finding that IA combined-targeting LNPs achieve 35% of the injected dose per gram (%ID/g) in the first-pass organ, the brain, among the highest reported. Thus, combining the affinity moiety and physicochemical strategies provides benefits that neither targeting method achieves alone.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · RNA Interference and Gene Delivery · Lipid Membrane Structure and Behavior
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Drexel University, School of Biomedical Engineering, Philadelphia, Pennsylvania 19104, United States
University of Pennsylvania, School of Systems Pharmacology and Translational Therapeutics, Philadelphia, Pennsylvania 19104, United States
University of Pennsylvania, Department of Bioengineering, Philadelphia, Pennsylvania 19104, United States
Funding
Division of Cancer Prevention, National Cancer Institute · U.S. Department of Health and Human Services · American Heart Association
References (79)
Show source-provided references
1. 10.1038/natrevmats.2016.1410.1038/natrevmats.2016.14 ↗
2. 10.1021/acsnano.9b0138310.1021/acsnano.9b01383 ↗
3. 10.1021/acsnano.1c0976210.1021/acsnano.1c09762 ↗
4. 10.1038/s41563-020-0755-z10.1038/s41563-020-0755-z ↗
5. 10.1089/humc.2013.08210.1089/humc.2013.082 ↗
6. 10.1016/0006-291X(79)92123-510.1016/0006-291X(79)92123-5 ↗
7. 10.1016/S0021-9258(17)44020-810.1016/S0021-9258(17)44020-8 ↗
8. 10.1126/science.742320310.1126/science.7423203 ↗
9. 10.1042/bst003061310.1042/bst0030613 ↗
10. 10.1038/265407a010.1038/265407a0 ↗
11. 10.1038/235339a010.1038/235339a0 ↗
12. 10.2174/157016105277389810.2174/1570161052773898 ↗
13. 10.1016/j.jphotobiol.2015.10.01710.1016/j.jphotobiol.2015.10.017 ↗
14. 10.1097/00003246-199804000-0002310.1097/00003246-199804000-00023 ↗
15. 10.1182/blood-2017-04-77993410.1182/blood-2017-04-779934 ↗
16. 10.1007/s13205-020-2144-310.1007/s13205-020-2144-3 ↗
17. Xu L. · Mol. Cancer Ther. · 2002 · 1 · 337
18. 10.1016/S1368-7646(03)00082-710.1016/S1368-7646(03)00082-7 ↗
19. 10.1186/s12885-016-2385-z10.1186/s12885-016-2385-z ↗
20. 10.2147/IJN.S2377110.2147/IJN.S23771 ↗
21. 10.1016/S0928-0987(01)00147-610.1016/S0928-0987(01)00147-6 ↗
22. 10.1002/btm2.1000310.1002/btm2.10003 ↗
23. 10.1002/btm2.1014310.1002/btm2.10143 ↗
24. 10.1073/pnas.110637910810.1073/pnas.1106379108 ↗
25. 10.1038/nnano.2012.7310.1038/nnano.2012.73 ↗
26. 10.1073/pnas.091060310610.1073/pnas.0910603106 ↗
27. 10.1038/nbt140210.1038/nbt1402 ↗
28. 10.1038/s41565-020-0669-610.1038/s41565-020-0669-6 ↗
29. 10.1038/s41596-022-00755-x10.1038/s41596-022-00755-x ↗
30. 10.1016/j.jconrel.2022.03.04610.1016/j.jconrel.2022.03.046 ↗
31. 10.1021/acs.nanolett.9b0424610.1021/acs.nanolett.9b04246 ↗
32. 10.1021/acs.nanolett.1c0250310.1021/acs.nanolett.1c02503 ↗
33. 10.1186/s12883-017-0948-510.1186/s12883-017-0948-5 ↗
34. 10.1021/acsnano.2c0827510.1021/acsnano.2c08275 ↗
35. 10.1371/journal.pone.020245610.1371/journal.pone.0202456 ↗
36. 10.1016/j.jconrel.2018.10.01510.1016/j.jconrel.2018.10.015 ↗
37. 10.1016/j.addr.2020.06.01310.1016/j.addr.2020.06.013 ↗
38. 10.1016/j.jconrel.2023.02.03710.1016/j.jconrel.2023.02.037 ↗
39. 10.1038/mt.2008.12710.1038/mt.2008.127 ↗
40. 10.1021/acs.bioconjchem.8b0056410.1021/acs.bioconjchem.8b00564 ↗
41. 10.1016/j.jconrel.2016.05.04010.1016/j.jconrel.2016.05.040 ↗
42. 10.1002/btm2.1005010.1002/btm2.10050 ↗
43. 10.1021/nn302687n10.1021/nn302687n ↗
44. 10.1073/pnas.25166239810.1073/pnas.251662398 ↗
45. 10.1158/1535-7163.MCT-06-017210.1158/1535-7163.MCT-06-0172 ↗
46. 10.1590/s2175-9790201800000100710.1590/s2175-97902018000001007 ↗
47. 10.1165/rcmb.2020-0306TR10.1165/rcmb.2020-0306TR ↗
48. Arthur, R. CordenPharma increases xRNA-based capabilities with LNP formulation investment in Italy. https://www.biopharma-reporter.com/Article/2022/06/02/CordenPharma-increases-xRNA-based-capabilities-with-LNP-formulation-investment-in-Italy (accessed 2023–11–01).
49. 10.1038/d41573-023-00002-210.1038/d41573-023-00002-2 ↗
50. 10.14740/jocmr491510.14740/jocmr4915 ↗
51. 10.1172/JCI6033110.1172/JCI60331 ↗
52. 10.1056/NEJM20000504342180610.1056/NEJM200005043421806 ↗
53. 10.4187/respcare.0471610.4187/respcare.04716 ↗
54. 10.1080/17476348.2020.180436510.1080/17476348.2020.1804365 ↗
55. 10.1080/13543784.2020.169953110.1080/13543784.2020.1699531 ↗
56. 10.1073/pnas.211627111910.1073/pnas.2116271119 ↗
57. 10.1016/j.jconrel.2023.07.05810.1016/j.jconrel.2023.07.058 ↗
58. 10.1016/j.jconrel.2021.11.02210.1016/j.jconrel.2021.11.022 ↗
59. 10.1038/s41565-021-01030-y10.1038/s41565-021-01030-y ↗
60. 10.1038/s41467-020-16248-y10.1038/s41467-020-16248-y ↗
61. 10.1371/journal.pone.018547410.1371/journal.pone.0185474 ↗
62. 10.1038/s41598-022-14618-810.1038/s41598-022-14618-8 ↗
63. 10.1073/pnas.191201211710.1073/pnas.1912012117 ↗
64. 10.3390/pharmaceutics1410223710.3390/pharmaceutics14102237 ↗
65. 10.1073/pnas.181127611510.1073/pnas.1811276115 ↗
66. 10.1016/j.nano.2016.12.01910.1016/j.nano.2016.12.019 ↗
67. 10.1146/annurev-bioeng-121219-02423910.1146/annurev-bioeng-121219-024239 ↗
68. 10.1021/acsnano.1c1137410.1021/acsnano.1c11374 ↗
69. 10.1038/s41467-018-05079-710.1038/s41467-018-05079-7 ↗
70. 10.1038/s41565-021-00997-y10.1038/s41565-021-00997-y ↗
71. 10.1016/j.ymthe.2024.03.00410.1016/j.ymthe.2024.03.004 ↗
72. 10.1016/j.addr.2022.11418010.1016/j.addr.2022.114180 ↗
73. 10.1016/j.jconrel.2019.03.00810.1016/j.jconrel.2019.03.008 ↗
74. 10.1002/adma.20231202610.1002/adma.202312026 ↗
75. 10.1016/j.jconrel.2021.12.02710.1016/j.jconrel.2021.12.027 ↗
76. 10.1126/science.122956810.1126/science.1229568 ↗
77. 10.1155/2018/126491310.1155/2018/1264913 ↗
78. 10.1007/s00011-022-01645-410.1007/s00011-022-01645-4 ↗
79. 10.1097/SHK.000000000000049910.1097/SHK.0000000000000499 ↗